Generalized Lichen Nitidus Following Anti–PD-1 Antibody Treatment

Abstract

Blinded ratings of validated photoscales showed significant improvement in upper and lower cheek fullness. Rater estimates of mean participant age showed a significant monotonic decrease from 50.8 years at baseline to 49.6 years at 8 weeks and 48.1 years at 20 weeks. Participants were highly satisfied, noting significant improvement in 18 of 20 facial features.This study had limitations that may reduce its external validity. The sample was small, exclusively of middle-aged women, there were numerous dropouts, and there was no control group in the study. Another limitation is that participants were self-selected and may have been particularly willing to continue with an exercise regimen.In conclusion, a regimen of at-home facial exercises maintained for 20 weeks seemed to improve mid-face and lower face fullness. The mechanism may be exercise-actuated hypertrophy of cheek and other muscles. Further research is warranted to isolate the causes and effects of exercise-related changes and to assess the generalizability of these findings.

Upregulated programmed death ligand 1 expression in nivolumab‐induced lichen nitidus: A follow‐up report with an immunohistochemical analysis

“…As the nivolumab treatment was continued, lesions spread to the whole body as reported previously. 2 Hematoxylin-eosin staining of the skin biopsy specimen confirmed the diagnosis of LN (Fig. 1c).…”

“…Takayoshi KOMATSU-FUJII, 1,2 Saeko NAKAJIMA, 1 Masashi IWATA, 1 Tatsuki KATAOKA, 3 Masahiro HIRATA, 3 Takashi NOMURA, 1 Kenji KABASHIMA 1,4…”

“…1 Recently, we reported a case of nivolumab-induced generalized lichen nitidus (LN). 2 However, little is known about the immunohistochemical status of LN as a dermatological irAE. Here, we conducted immunohistochemical analysis of nivolumab-induced LN and compared it with conventional LN and lichen planus (LP).…”

Wong-type dermatomyositis during anti–PD-1 therapy

“…Immune-related adverse events associated with PD-1 inhibitors commonly involve the skin, and reports of vitiligo, psoriasis, lichenoid dermatitis, eczematous dermatitis, and lupus-like reactions have entered the literature. 1 , 2 There is 1 report of an inflammatory myopathy complicating nivolumab therapy that was described as dermatomyositis sine dermatitis and 1 case of dermatomyositis with classic cutaneous features induced by nivolumab. 4 , 5 However, there are no reports of Wong-type dermatomyositis during anti–PD-1 therapy.…”

“…Checkpoint inhibitors used for cancer immunotherapy may also result in autoimmunity. 1 , 2 We present a case of Wong-type dermatomyositis complicating treatment with nivolumab, an inhibitor of the programmed cell death 1 (PD-1) receptor. Wong-type dermatomyositis is a rare variant of classic dermatomyositis with concurrent clinical and histopathologic findings mimicking pityriasis rubra pilaris.…”